Clinical Trial Update: QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study (QUILT-3.010) evaluating gemcitabine and nab-paclitaxel with or without NPC-1C in pancreatic cancer has been terminated; results were posted o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• NPC-1C (NPC-1C)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Precision Biologics, Inc | Conditions: Pancreatic Cancer, Adult | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-05-07